A VEGFR-3 Antagonist Increases IFN-γ Expression on Low Functioning NK Cells in Acute Myeloid Leukemia

[1]  Z. Berneman,et al.  Natural killer cell immune escape in acute myeloid leukemia , 2012, Leukemia.

[2]  G. Bernardini,et al.  CX3CR1 expression defines 2 KLRG1+ mouse NK-cell subsets with distinct functional properties and positioning in the bone marrow. , 2011, Blood.

[3]  G. Koh,et al.  T lymphocytes negatively regulate lymph node lymphatic vessel formation. , 2011, Immunity.

[4]  G. V. Chaitanya,et al.  Differential cytokine responses in human and mouse lymphatic endothelial cells to cytokines in vitro. , 2010, Lymphatic research and biology.

[5]  W. Kamps,et al.  High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. , 2010, Blood.

[6]  Y. Yoon,et al.  CD31+ Cells Represent Highly Angiogenic and Vasculogenic Cells in Bone Marrow: Novel Role of Nonendothelial CD31+ Cells in Neovascularization and Their Therapeutic Effects on Ischemic Vascular Disease , 2010, Circulation research.

[7]  E. Scott,et al.  Leukemia regression by vascular disruption and antiangiogenic therapy. , 2010, Blood.

[8]  Y. Yonemitsu,et al.  Autocrine loop between vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 positively regulates tumor-associated lymphangiogenesis in oral squamoid cancer cells. , 2009, The American journal of pathology.

[9]  M. Skobe,et al.  Inflamed Lymphatic Endothelium Suppresses Dendritic Cell Maturation and Function via Mac-1/ICAM-1-Dependent Mechanism1 , 2009, The Journal of Immunology.

[10]  E. Estey,et al.  Acute Myelogenous Leukemia , 2005 .

[11]  D. Campana,et al.  Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. , 2009, Cancer research.

[12]  B. Cho,et al.  The Activating Killer Cell Immunoglobulin-Like Receptors as Important Determinants of Acute Graft-Versus Host Disease in Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia , 2007, Transplantation.

[13]  N. Huntington,et al.  Developmental pathways that generate natural-killer-cell diversity in mice and humans , 2007, Nature Reviews Immunology.

[14]  K. Alitalo,et al.  Molecular regulation of angiogenesis and lymphangiogenesis , 2007, Nature Reviews Molecular Cell Biology.

[15]  M. Detmar,et al.  New insights into the molecular control of the lymphatic vascular system and its role in disease. , 2006, The Journal of investigative dermatology.

[16]  X. Shao,et al.  Influence of IFN- alpha and IFN- gamma on lymphangiogenesis. , 2006, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[17]  C. Kalberer,et al.  Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice , 2005, Leukemia.

[18]  D. Campana,et al.  Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. , 2005, Blood.

[19]  C. Kalberer,et al.  Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias. , 2005, Blood.

[20]  M. Smyth,et al.  Activation of NK cell cytotoxicity. , 2005, Molecular immunology.

[21]  J. Sleeman,et al.  MAZ51, an indolinone that inhibits endothelial cell and tumor cell growth in vitro, suppresses tumor growth in vivo , 2004, International journal of cancer.

[22]  D. Olive,et al.  Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. , 2002, Blood.

[23]  Rakesh K Jain,et al.  Lymphatic Metastasis in the Absence of Functional Intratumor Lymphatics , 2002, Science.

[24]  S. Rafii,et al.  Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. , 2002, Blood.

[25]  Katia Perruccio,et al.  Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.

[26]  T. Blankenstein,et al.  Tumor Rejection by Disturbing Tumor Stroma Cell Interactions , 2001, The Journal of experimental medicine.

[27]  M. Caligiuri,et al.  The biology of human natural killer-cell subsets. , 2001, Trends in immunology.

[28]  H. Fathallah-Shaykh,et al.  Gene Transfer of IFN-γ into Established Brain Tumors Represses Growth by Antiangiogenesis , 2000, The Journal of Immunology.

[29]  H. Fathallah-Shaykh,et al.  Gene transfer of IFN-gamma into established brain tumors represses growth by antiangiogenesis. , 2000, Journal of immunology.

[30]  F Lacombe,et al.  Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia , 1997, Leukemia.

[31]  S. Ergün,et al.  Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia , 1997, Leukemia.

[32]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[33]  K. Alitalo,et al.  Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[34]  T. Hirano,et al.  Participation of the cytokines interleukin 6, tumor necrosis factor-alpha, and interleukin 1-beta secreted by acute myelogenous leukemia blasts in autocrine and paracrine leukemia growth control. , 1989, The Journal of clinical investigation.

[35]  L. Lanier,et al.  A model for the differentiation of human natural killer cells. Studies on the in vitro activation of Leu-11+ granular lymphocytes with a natural killer-sensitive tumor cell, K562 , 1985, The Journal of experimental medicine.

[36]  J. Ortaldo,et al.  Natural killer cells: their roles in defenses against disease. , 1981, Science.

[37]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.